Artiva Biotherapeutics, Inc. ARTV Gain (loss) on mark-to-market of Escrowed Shares
Gain (loss) on mark-to-market of Escrowed Shares at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnDerivatives.
The official record: Artiva Biotherapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s gain (loss) on mark-to-market of escrowed shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s gain (loss) on mark-to-market of escrowed shares?
- Artiva Biotherapeutics, Inc. (ARTV) reported gain (loss) on mark-to-market of escrowed shares of $0 in Q4 2025.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s gain (loss) on mark-to-market of escrowed shares?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s gain (loss) on mark-to-market of escrowed shares has grown at a -100.0% compound annual growth rate (CAGR), from -$707K to $0.
- What does gain (loss) on mark-to-market of escrowed shares mean?
- Represents the non-cash impact of changes in the fair value of derivative instruments or escrowed equity arrangements held by the company. This adjustment is necessary to reconcile net income to cash flow from operations by removing gains or losses that do not involve immediate cash exchange.